<h3>Introduction</h3> Intramuscular epinephrine is first-line treatment for severe allergic reactions. However, patients/caregivers often hesitate before using an epinephrine injectable device, endangering themselves or their child because progression of an allergic reaction can be quick and unpredictable. The time people wait before device use, what triggers use, and reasons for hesitation are not understood. Insight was sought regarding time to device use after symptom development and triggers for use. <h3>Methods</h3> A 20-minute double-blind survey of patients/caregivers who used an epinephrine injectable device within the preceding 12 months was conducted (exempt from IRB approval). Respondents were asked questions about their/their child's allergy, symptoms that triggered device use, and reasons for hesitation. <h3>Results</h3> A total of 200 individuals responded (caregivers and patients, n=100 each). Average time between symptom development and device use was 8.8 minutes, and the needle in the injectable device was the main reason for delay. When respondents were presented with a needle-free delivery device concept for administering epinephrine, estimated time to use was reduced to 4.9 minutes. A needle-free device was perceived as easier/less complicated and less painful to use; the lack of a needle would eliminate harm errors (e.g., striking bone or accidental intravenous injection). Respondents noted that they would be more likely to use a needle-free device at the onset of symptoms. <h3>Conclusion</h3> A needle-free option for administering epinephrine would be used more quickly after symptoms developed and would be easier to use versus an injectable device. This underscores the need to develop epinephrine modalities utilizing a non-needle-based delivery system.